During the last session, Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)’s traded shares were 14.34 million, with the beta value of the company hitting 2.09. The 52-week high for the TNXP share is $22.14, that puts it down -14660.0 from that peak though still a striking 20.0% gain since the share price plummeted to a 52-week low of $0.12. The company’s market capitalization is $19.94M, and the average intraday trading volume over the past 10 days was 18.3 million shares, and the average trade volume was 30.72 million shares over the past three months.
Tonix Pharmaceuticals Holding Corp (TNXP) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. TNXP has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -2.93.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) trade information
Tonix Pharmaceuticals Holding Corp (TNXP) registered a -5.89% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -5.89% in intraday trading to $0.15, hitting a weekly high. The stock’s 5-day price performance is -9.47%, and it has moved by 11.34% in 30 days. Based on these gigs, the overall price performance for the year is -99.23%. The short interest in Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) is 5.46 million shares and it means that shorts have 0.23 day(s) to cover.
Tonix Pharmaceuticals Holding Corp (TNXP) estimates and forecasts
Statistics show that Tonix Pharmaceuticals Holding Corp has outperformed its competitors in share price, compared to the industry in which it operates. Tonix Pharmaceuticals Holding Corp (TNXP) shares have gone down -97.35% during the last six months, with a year-to-date growth rate more than the industry average at 91.78% against 17.60. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 95.00% this quarter and then jump 89.20% in the quarter after that. In the rating firms’ projections, revenue will increase 59.40% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 3.08M as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 3.4M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 3.99M and 3.78M respectively. In this case, analysts expect current quarter sales to shrink by -22.80% and then drop by -10.00% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 79.31%. While earnings are projected to return 31.99% in 2024.
TNXP Dividends
Tonix Pharmaceuticals Holding Corp is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)’s Major holders
Tonix Pharmaceuticals Holding Corp insiders own 0.17% of total outstanding shares while institutional holders control 0.17%, with the float percentage being 0.17%.
